Overall, we propose that a combination of small molecule KDM1A inhibitors and CAR T cell therapy might present a promising strategy to efficiently attack neuroblastoma and other solid tumor entities with low or heterogeneous antigen expression by enabling eradication of an antigen-negative tumor fraction. Here, KDM1A is linked to neuroblastoma.